These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32547043)

  • 1. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
    Linari S; Castaman G
    Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
    Kenet G; Fujii T
    Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study.
    Schultz NH; Glosli H; Bjørnsen S; Holme PA
    Res Pract Thromb Haemost; 2021 Jul; 5(5):e12561. PubMed ID: 34263107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience.
    Castaman G; Linari S; Pieri L; Carulli C; Prosperi P; Tonelli P; Demartis F; Fjerza R; Attanasio M; Coppo M; Salvianti F
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.
    Yada K; Nogami K
    J Blood Med; 2019; 10():171-181. PubMed ID: 31308776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
    Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
    Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays.
    Kizilocak H; Marquez-Casas E; Phei Wee C; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Jan; 27(1):164-172. PubMed ID: 33245833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents.
    Hartmann R; Feenstra T; Valentino L; Dockal M; Scheiflinger F
    J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
    Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
    J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
    Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
    TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
    Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
    Callaghan MU; Negrier C; Paz-Priel I; Chang T; Chebon S; Lehle M; Mahlangu J; Young G; Kruse-Jarres R; Mancuso ME; Niggli M; Howard M; Bienz NS; Shima M; Jiménez-Yuste V; Schmitt C; Asikanius E; Levy GG; Pipe SW; Oldenburg J
    Blood; 2021 Apr; 137(16):2231-2242. PubMed ID: 33512413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
    Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
    Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.